Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of the phase III LUME-colon 1 study.
Authors
Van Cutsem, EYoshino, T
Lenz, H
Lonardi, S
Falcone, A
Limon, M
Saunders, Mark P
Sobrero, A.
Maiello, E.
Park, Y.S.
Monteagudo, R
Hong, Y
Tomasek, J
Taniguchi, H
Ciardiello, F
Hocke, J
Oum'hamed, Z
Vlassak, S
Studeny, M
Tabernero, J
Affiliation
Digestive Oncology, University Hospitals Leuven - Campus Gasthuisberg, LeuvenIssue Date
2016-10-01
Metadata
Show full item recordCitation
Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: results of the phase III LUME-colon 1 study. 2016, 27(suppl_6):LBA20_PR Annals of OncologyJournal
Annals of OncologyDOI
10.1093/annonc/mdw435.12Additional Links
https://academic.oup.com/annonc/article/2800521/gastrointestinalType
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdw435.12